The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Dendreon (I)
Honoraria - Bayer; Genomic Health; Janssen; MDxHealth
Consulting or Advisory Role - MDxHealth
Patents, Royalties, Other Intellectual Property - University of Colorado Cancer Center
Travel, Accommodations, Expenses - Bayer
Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124.
 
L. Michael Glode
Leadership - Gonex; ProTechSure Scientific
Stock and Other Ownership Interests - Gonex; ProTechSure Scientific
Consulting or Advisory Role - Janssen
Patents, Royalties, Other Intellectual Property - Patents held by the University of Colorado in my name relating to GnRH and EGF toxin conjugates, Silibinin
Travel, Accommodations, Expenses - Janssen
 
Catherine M. Tangen
No Relationships to Disclose
 
Maha Hussain
Consulting or Advisory Role - AstraZeneca; Essa; Johnson & Johnson; Synthon
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
Gregory P. Swanson
No Relationships to Disclose
 
David Peter Wood
No Relationships to Disclose
 
Wael Sakr
No Relationships to Disclose
 
Nancy Ann Dawson
Honoraria - Amgen; Astellas Pharma; Bayer; Eisai; Genentech/Roche; Janssen Biotech; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Janssen Scientific Affairs
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Eisai; Genentech/Roche; Janssen Biotech; Novartis; Pfizer; Sanofi
Research Funding - Acceleron Pharma (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Pfizer (Inst); Roche/Genentech (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Naomi B. Haas
Stock and Other Ownership Interests - TetraLogic Pharmaceuticals (I)
Expert Testimony - Lilly (I)
 
Thomas W. Flaig
Leadership - Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology
Honoraria - BN ImmunoTherapeutics; GTx
Consulting or Advisory Role - GTX
Research Funding - Aragon Pharmaceuticals; Bavarian Nordic; Bristol-Myers Squibb; Cougar Biotechnology; Dendreon; Exelixis; GTx; Janssen Oncology; Medivation; Novartis; Pfizer; Roche/Genentech; Sanofi; Sotio
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents in which I am an inventor. These are related to bladder cancer treatment of early stage disease.
Travel, Accommodations, Expenses - Bavarian Nordic; GTx
 
Tanya B. Dorff
Honoraria - Astellas Pharma; Dendreon; Medivation; Pfizer
Consulting or Advisory Role - Bayer; Dendreon; Genentech
Speakers' Bureau - Astellas Pharma; Dendreon; Pfizer
Research Funding - Bristol-Myers Squibb
 
Daniel W. Lin
Consulting or Advisory Role - Astellas Pharma; Bayer; Myriad Genetics
Research Funding - GenomeDx (Inst); Genomic Health (Inst)
 
E. David Crawford
No Relationships to Disclose
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Novartis; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Novartis; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Dendreon; Endocyte; Janssen Oncology; Mannkind; Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AVEO; Bayer; BIND Biosciences; Cerulean Pharma; Churchill Pharmaceuticals; Genentech/Roche; HERON; Janssen Biotech; Labceutics; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Ian Murchie Thompson
Consulting or Advisory Role - Exosome diagnostics; Magforce
Patents, Royalties, Other Intellectual Property - I have been involved in the establishment of a new company - NanoTX Therapeutics to commercialize a novel therapy for glioblastoma for our cancer center. I am on the Board of Directors and it has intellectual property developed by our cancer center.; I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme